BioCentury
ARTICLE | Clinical News

Avastin bevacizumab regulatory update

May 27, 2013 7:00 AM UTC

The U.K.'s NICE issued final guidances recommending against the use of Avastin bevacizumab from Roche for its 2 approved advanced ovarian cancer indications. NICE recommended against Avastin in combination with carboplatin and paclitaxel for first-line treatment and to treat first recurrence of platinum-sensitive cancer in combination with gemcitabine and carboplatin in patients who have not received prior therapy with Avastin or other VEGF inhibitors or VEGF receptor-targeted agents. The final guidances are in line with final appraisal determinations (FAD) issued in March and April, respectively (see BioCentury, April 1 & April 29). ...